This is a routine executive appointment with no immediate financial impact. Monitor upcoming quarterly results for any operational execution changes under the new President. The hire signals focus on scaling commercial operations, but no guidance or financial data was provided.
Price Chart
Executive Summary
GeneDx appointed Mark Gardner as President, effective June 15, 2026, to oversee lab and commercial operations. Gardner, a former Quest Diagnostics executive, received a compensation package including a $530,000 base salary, 65% target bonus, and $2,000,000 in restricted stock units. This is a routine executive hire with no financial data or guidance provided.
Key Facts
- Mark Gardner appointed President effective June 15, 2026, reporting to CEO Katherine Stueland
- Gardner previously served as SVP of Molecular Genomics and Oncology at Quest Diagnostics (Sept 2022 – June 2026)
- Employment agreement: $530,000 annual base salary, 65% target bonus, $2,000,000 in RSUs vesting over 4 years
- Bryan Dechairo transitions to lead product, technology and innovation initiatives
- No financial results, guidance, or material operational metrics disclosed in the filing
Financial Impact
Compensation package for new President: $530,000 base salary, $344,500 target bonus, $2,000,000 in RSUs
Risk Factors
- No financial data or guidance provided to assess impact on operations
- Historical performance on WGS reports shows negative average T+20 returns (-4.79%) and low win rate (25%), suggesting limited market reaction to similar filings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-043431 |
| Exhibit: exhibit991-6162026pressrel.htm | 0001628280-26-043431 |
| Document: 0001628280-26-043431-index-headers.html | 0001628280-26-043431 |
| Document: 0001628280-26-043431-index.html | 0001628280-26-043431 |
| Document: 0001628280-26-043431.txt | 0001628280-26-043431 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | Insider Cluster | $85.27 $101.10 | ▲ +18.57% | ▲ +18.79% | $73.09 (−14.28%) |
Sep 1, 2026 4w ago | 144 | $86.72 $83.96 | ▼ −3.18% | ▼ −2.22% | $73.09 (−15.72%) |
Jul 27, 2026 9w ago | Press Release | $61.88 $67.86 | ▼ −9.66% | ▼ −7.39% | $73.09 (−18.12%) |
Jul 23, 2026 10w ago | Press Release | $63.38 $68.96 | ▼ −8.80% | ▼ −8.33% | $73.09 (−15.32%) |
Jun 16, 2026 15w ago | 8-K | $60.60 $58.08 | ▼ −4.16% | ▼ −1.93% | $73.09 (+20.61%) |
Jun 11, 2026 16w ago | Institutional Cluster | $59.92 $59.01 | ▼ −1.52% | ▼ −2.19% | $73.09 (+21.98%) |
Jun 8, 2026 16w ago | Insider Cluster | $56.33 $61.32 | ▲ +8.86% | ▲ +6.45% | $73.09 (+29.75%) |
May 20, 2026 19w ago | Insider Cluster | $47.33 $50.15 | ▲ +5.96% | ▲ +4.36% | $73.09 (+54.43%) |
Mar 26, 2026 27w ago | Insider Cluster | $61.35 $66.20 | ▼ −7.91% | ▼ −6.27% | $73.09 (−19.14%) |
Mar 4, 2026 30w ago | Insider Cluster | $79.47 $85.10 | ▼ −7.08% | ▼ −8.42% | $73.09 (+8.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access